# Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia

> **NCT00769327** · PHASE2 · COMPLETED · sponsor: **Gruppo Italiano Malattie EMatologiche dell'Adulto** · enrollment: 129 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** imatinib mesylate
- **DRUG:** nilotinib
- **GENETIC:** cytogenetic analysis
- **GENETIC:** fluorescence in situ hybridization
- **GENETIC:** microarray analysis
- **GENETIC:** mutation analysis
- **GENETIC:** polymerase chain reaction
- **GENETIC:** polymorphism analysis
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00769327
- **Lead sponsor:** Gruppo Italiano Malattie EMatologiche dell'Adulto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02-09
- **Primary completion:** 2014-10
- **Final completion:** 2014-10-10
- **Target enrollment:** 129 (ACTUAL)
- **Last updated:** 2022-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00769327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00769327, "Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00769327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*